Captor Therapeutics ®

Grant projects

Logotypy

Grant projects co-funded by the National Centre for Research and Development

Elaboration of interaction assays suitable for screening of the chemical compounds used in a first-in-class drug development (POIR.04.01.02-00-0147/16-00).
- Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.4 "Regional research agendas" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund
  
  Project is realized by Consortium comprising: Institute of Immunology and Experimental Therapy Polish Academy of Sciences in Wroclaw, Captor Therapeutics Inc
  
  Value of the project: 4 314 375.00 PLN
  European Union financing: 3 834 558.00 PLN
  
  Goal and expected results of the project: development of scalable and sensitive high-throughput fluorescence assay allowing for rapid detection of active PROTAC compounds which induce degradation of pathological proteins.
Development and implementation of an innovative platform for the identification drug-like compounds (POIR.04.01.04-00-0116/16-00).
- Project carried out within the Measure 4.1 "Research and development", Sub-measure 4.1.1 "Application projects" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund
  
  Project realized by Consortium comprising: The National Centre of Research and Development Ltd, Captor Therapeutics Inc
  
  Value of the project: 4 968 788.76 PLN
  European Union financing: 4 260 002.76 PLN
  
  Goal and expected results: development of two-stage high-throughput screening assay for low molecular weight compounds which induce targeted protein degradation.
Development of first-in-class anti-inflammatory drugs specifically degrading disease modifying proteins (POIR.01.01.01-00-0747/16-00).
- Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1 "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund
  
  Value of the project: 32 164 999.43 PLN
  
  European Union financing: 24 460 751.26 PLN
  
  Goal and expected results: Development low molecular weight compunds inhibiting receptor proteins by applying the bispecific inductor degradation (BID) technology which will be drug candidates for patients ailed with rheumathoid arthritis or inflammatory bowel disease.
Small molecules as therapeutic intervention in multiple severe malignancies (POIR.01.01.01-00-0956/17-00).
- Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1 "Industrial research and developmend work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund
  
  Value of project: 35 902 013.75 PLN
  European Union financing: 27 683 098.00 PLN
  
  Goal and expected results of the project: Development and testing in the first stage of clinical tests of low molecular weight chemical compounds which will be future drug candidates in tumor therapies of non-small lung cancer and triple negative breast cancer.
Application of targeted protein degradation technology in the treatment of psoriasis and rheumatoid arthritis (POIR.01.02.00-00-0079/18).
- Project carried out within the Priority Axis I: Supporting R&D carried out by enterprises”, Measure 1.2 „Sectoral R&D programmes”, as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund
  
  Value of project: 37 130 943.75 PLN
  European Union financing: 29 558 070.00 PLN
  
  Goal and expected results of the project: Discovery and development novel, first in class oral drugs targeting key drivers of rheumatoid arthritis, psoriasis and ulcerative colitis.
Discovery and Development of First-in-Class of Small Molecule Degrader As a Drug Candidate For the Treatment of Colorectal Cancer (POIR.01.02.00-00-0073/18).
- Project carried out within the Priority Axis I: Supporting R&D carried out by enterprises”, Measure 1.2 „Sectoral R&D programmes”, as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund
  
  Value of project: 32 041 906.25 PLN
  European Union financing: 25 510 680.00 PLN
  
  Goal and expected results of the project: Development of first, oral targeted therapy focused on interruption of the main cause of colorectal cancer (CRC). The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.
Development of targeted oncogenic transcription factor degradation technology in the treatment of hepatocellular carcinoma (POIR.01.01.01-00-0740/19).
- Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1 "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.
  
  Value of the project: 36 389 016.25 PLN
  European Union financing: 28 959 643.00 PLN
  
  Goal of project: Development of a drug candidate in the treatment of hepatocellular carcinoma that allows the elimination of cancer cells through induced degradation of oncogenic transcription factor. The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.
Development of technological platform in the area of targeted protein degradation and its implementation on the pharmaceutical market (POIR.01.01.01-00-0931/19).
- Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1 "Industrial research and development work implemented by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.
  
  Value of the project: 10 135 628.75 PLN
  European Union financing: 7 759 469.50 PLN
  
  Goal and expected results of the project: Development and implementation of technological platform through generation of modular small molecules capable of inducing protein degradation upon recruitment of novel ubiquitin ligases.
Development of non-toxic ligase ligands and their application in the treatment of autoimmune diseases (POIR.01.01.01-00-0741/19).
- Project carried out within the Measure 1.1 "R&D projects of enterprises", Sub-measure 1.1.1 "Industrial research and development work implementet by enterprises" as part of the Operational Programme Smart Growth 2014-2020 co-funded by the European Regional Development Fund.
  
  Value of the project: 34 441 900.00 PLN
  European Union financing: 27 411 400.00 PLN
  
  Goal and expected results of the project: Development of a drug candidate in the treatment of autoimmune diseases through generation of non-toxic ligase ligands. The efficacy and bioavailability of the drug candidate will be tested in preclinical phase, followed by the Phase I clinical trials.